Evolution of neuroinflammation across the lifespan of individuals with Down syndrome


Por: Flores-Aguilar, L, Iulita, MF, Kovecses, O, Torres, MD, Levi, SM, Zhang, YA, Askenazi, M, Wisniewski, T, Busciglio, J, Cuello, AC

Publicada: 1 dic 2020
Resumen:
Epidemiological and experimental studies suggest that a disease-aggravating neuroinflammatory process is present at preclinical stages of Alzheimer's disease. Given that individuals with Down syndrome are at increased genetic risk of Alzheimer's disease and therefore develop the spectrum of Alzheimer's neuropathology in a uniform manner, they constitute an important population to study the evolution of neuroinflammation across the Alzheimer's continuum. Therefore, in this cross-sectional study, we characterized the brain inflammatory profile across the lifespan of individuals with Down syndrome. Microglial morphology and inflammatory cytokine expression were analysed by immunohistochemistry and electrochemiluminescent-based immunoassays in the frontal cortex from foetuses to adults with Down syndrome and control subjects (16 gestational weeks to 64 years), totalling 127 cases. Cytokine expression in mixed foetal primary cultures and hippocampus of adults with Down syndrome, as well as the effects of sex on cytokine expression were also analysed. A higher microglial soma size-to-process length ratio was observed in the frontal cortex of children and young adults with Down syndrome before the development of full-blown Alzheimer's pathology. Moreover, young adults with Down syndrome also displayed increased numbers of rod-like microglia. Increased levels of interleukin-8 and interleukin-10 were observed in children with Down syndrome (1-10 years; Down syndrome n=5, controls n=10) and higher levels of interleukin-1 beta, interleukin-1 alpha, interleukin-6, interleukin-8, interleukin-10, interleukin-15, eotaxin-3, interferon gamma-induced protein 10, macrophage-derived chemokine, and macrophage inflammatory protein-beta, were found in young adults with Down syndrome compared to euploid cases (13-25 years, Down syndrome n=6, controls n=24). Increased cytokine expression was also found in the conditioned media of mixed cortical primary cultures from second trimester foetuses with Down syndrome (Down syndrome n=7, controls n=7). Older adults with Down syndrome (39-68 years, Down syndrome n=22, controls n=16) displayed reduced levels of interleukin-10, interleukin-12p40, interferon-gamma and tumour necrosis factor-alpha. Microglia displayed larger somas and shorter processes. Moreover, an increase in dystrophic microglia and rod-like microglia aligning to neurons harbouring tau pathology were also observed. Sex stratification analyses revealed that females with Down syndrome had increased interleukin-6 and interleukin-8 levels compared to males with Down syndrome. Finally, multivariate projection methods identified specific cytokine patterns among individuals with Down syndrome. Our findings indicate the presence of an early and evolving neuroinflammatory phenotype across the lifespan in Down syndrome, a knowledge that is relevant for the discovery of stage-specific targets and for the design of possible anti-inflammatory trials against Alzheimer's disease in this population.

Filiaciones:
Flores-Aguilar, L:
 McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada

Iulita, MF:
 McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada

 Univ Autonoma Barcelona, Biomed Res Inst St Pau, Hosp Santa Creu & St Pau, St Pau Memory Unit,Dept Neurol, Barcelona, Spain

 Hosp Santa Creu & Sant Pau, Fdn Catalana Sindrome, Alzheimer Unit, Barcelona, Spain

Kovecses, O:
 McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada

Torres, MD:
 Univ Calif Irvine, UCI MIND Inst, Dept Neurobiol & Behav, Irvine, CA USA

 Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92717 USA

Levi, SM:
 McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada

Zhang, YA:
 NYU, Grossman Sch Med, Div Biostat, New York, NY USA

Askenazi, M:
 Biomed Hosting LLC, Arlington, MA USA

Wisniewski, T:
 NYU, Ctr Cognit Neurol, Grossman Sch Med, Dept Neurol, New York, NY 10016 USA

 NYU, Grossman Sch Med, Ctr Cognit Neurol, Dept Pathol, 550 1St Ave, New York, NY 10016 USA

Busciglio, J:
 Univ Calif Irvine, UCI MIND Inst, Dept Neurobiol & Behav, Irvine, CA USA

 Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92717 USA

Cuello, AC:
 McGill Univ, Dept Anat & Cell Biol, Montreal, PQ, Canada

 McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ, Canada

 McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada

 Univ Oxford, Dept Pharmacol, Oxford, England
ISSN: 00068950





BRAIN
Editorial
OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 143 Número: 12
Páginas: 3653-3671
WOS Id: 000615920000026
ID de PubMed: 33206953
imagen Bronze

MÉTRICAS